Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
0(0%)
Results Posted
17%(1 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_2
1
14%
Ph phase_4
5
71%

Phase Distribution

0

Early Stage

1

Mid Stage

5

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
1(16.7%)
Phase 4Post-market surveillance
5(83.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(6)
Terminated(1)

Detailed Status

Completed6
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
85.7%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (16.7%)
Phase 45 (83.3%)

Trials by Status

completed686%
terminated114%

Recent Activity

0 active trials
Showing 5 of 7
completed

The Predictive Value of On-treatment Virological Response for Sustained Virological Response in Chronic Hepatitis C

NCT01464008
completedphase_4

Four Arms, Multicenter Study of Tailored Regimens With Peginterferon Plus Ribavirin for Genotype 2 Chronic Hepatitis C

NCT00540345
terminatedphase_4

Combination Therapy With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C Genotype 2 or 3 Infection Who Previously Have Relapsed After Therapy With Pegylated Interferon and Ribavirin

NCT00641654
completedphase_2

Retreatment With High Doses of pegIFN Alfa-2a and Ribavirin of Previous Nonresponders HIV-coinfected Patients With Cirrhosis Due to HCV 1-4

NCT01006031
completedphase_4

Low Dose Peginterferon-α 2a for Chronic Hepatitis C, Genotypes 2 or 3, in HIV-coinfected Patients

NCT00553930
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT01464008

The Predictive Value of On-treatment Virological Response for Sustained Virological Response in Chronic Hepatitis C

Completed
NCT00540345Phase 4

Four Arms, Multicenter Study of Tailored Regimens With Peginterferon Plus Ribavirin for Genotype 2 Chronic Hepatitis C

Completed
NCT00641654Phase 4

Combination Therapy With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C Genotype 2 or 3 Infection Who Previously Have Relapsed After Therapy With Pegylated Interferon and Ribavirin

Terminated
NCT01006031Phase 2

Retreatment With High Doses of pegIFN Alfa-2a and Ribavirin of Previous Nonresponders HIV-coinfected Patients With Cirrhosis Due to HCV 1-4

Completed
NCT00553930Phase 4

Low Dose Peginterferon-α 2a for Chronic Hepatitis C, Genotypes 2 or 3, in HIV-coinfected Patients

Completed
NCT00491179Phase 4

Retreatment of Dialysis Patients With Chronic Hepatitis C With Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin

Completed
NCT00629967Phase 4

A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-1 Patients

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7